.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CA54_TamsulosinAndTadalafil.TamsulosinAndTadalafil .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CA54_TamsulosinAndTadalafil.TamsulosinAndTadalafil| name: | TamsulosinAndTadalafil | |
| ATC code: | G04CA54 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 34 | L |
| clearance: | 3.5 | L/h |
| other parameters in model implementation | ||
Tamsulosin and tadalafil is a fixed-dose combination used primarily in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult men, with tamsulosin acting as an alpha-1 adrenergic antagonist and tadalafil as a phosphodiesterase-5 inhibitor. The combination is approved and used today for such indications in some countries.
No published pharmacokinetic models providing compartmental parameters for the tamsulosin and tadalafil fixed-dose combination exist as of June 2024. Therefore, estimated parameters are based on known pharmacokinetics of individual oral tamsulosin and tadalafil in healthy adult males.